Early Data Show TNB-383B to be Safe, Effective for Heavily Treated Myeloma
News
Teneobio‘s bispecific antibody TNB-383B was found to be well-tolerated and induced a high response rate among people with heavily treated multiple myeloma in an ongoing Phase 1 trial. Preliminary data ... Read more